PREVENTING MDR GRAM-NEGATIVE HOSPITAL ACQUIRED INFECTIONS
Hospital acquired infections are leading cause of non-cardiac death in intensive care units (ICUs).
New synthetic glycoconjugate preventing (ICU)-acquired infections by eliciting protective immunity against MDR bacteria.
Synthetic polymer able to elicit protective immunity against MDR
Faster developed immunity than vaccines
Cost-effective treatment resulting in potential savings to the health system
The present invention relates to the field of therapeutics and, more in
particular, to agents and compositions for the prevention and/or
treatment of infections caused by bacteria. But the group is currently
working in other applications of interest.
The study has shown that removal of anti-Gal
antibodies mediated by GAS prevents sepsis and reduces cytokine levels
in mice genetically modified so as to express anti-Gal antibodies.
has also been tested successfully in human serum, showing increased
bactericidal capacity in GAS-pre-treated serums. Toxicity preclinical
studies in house have been performed in primates successfully.
IP status: patent ongoing in national phases